410 likes | 1.16k Views
ACUTE PERICARDITIS. Emily O. Jenkins M.D. AM Report 7.13.09. Incidence. Exact incidence and prevalence are unknown Diagnosed in 0.1% of hospitalized patients and 5% of patients admitted for non-acute MI chest pain Observational study: 27.7 cases/100,000 population/year.
E N D
ACUTE PERICARDITIS Emily O. Jenkins M.D. AM Report 7.13.09
Incidence • Exact incidence and prevalence are unknown • Diagnosed in 0.1% of hospitalized patients and 5% of patients admitted for non-acute MI chest pain • Observational study: 27.7 cases/100,000 population/year
Etiology: Can be Tricky. . . • Standard diagnostic evaluations are oftentimes relatively low yield • One series elucidated a cause in only 16% of patients • Leading possibilities: • Neoplasia • Tuberculosis • Non-tuberculous infection • Rheumatic disease
Initial clinical and echocardiographic evaluation of patients with suspected acute pericarditis
Diagnostic Criteria • Chest pain: anterior chest, sudden onset, pleuritic; may decrease in intensity when leans forward, may radiate to one or both trapezius ridges • Pericardial friction rub: most specific, heard best at LSB • EKG changes: new widespread ST elevation or PR depression • Pericardial effusion: absence of does not exclude diagnosis of pericarditis • Supporting signs/symptoms: • Elevated ESR, CRP • Fever • leukocytosis
EKG Electrocardiogram in acute pericarditis showing diffuse upsloping ST segment elevations seen best here in leads II, III, aVF, and V2 to V6. There is also subtle PR segment deviation (positive in aVR, negative in most other leads). ST segment elevation is due to a ventricular current of injury associated with epicardial inflammation; similarly, the PR segment changes are due to an atrial current of injury which, in pericarditis, typically displaces the PR segment upward in lead aVR and downward in most other leads.
Pericardial Effusion Cardiomegaly due to a massive pericardial effusion. At least 200 mL of pericardial fluid must accumulate before the cardiac silhouette enlarges.
Tests • EKG • CXR • PPD • ANA • HIV • Blood cultures • Urgent echocardiogram if evidence of pericardial effusion • Not necessary: • Viral studies b/c yield is low and management is not altered
Treatment • NSAIDs + PPI • Aspirin (2-5 g/day) • Ibuprofen (300-800 mg q6-8H)* • Ketorolac • Theoretical concern that anti-platelet agents promote development of hemorrhagic pericardial effusion has not been substantiated • Colchicine (0.5-1 mg/day) : may prevent recurrence • Glucocorticoids (prednisone 1 mg/kg/day): ? increased rate of complications. Should be restricted to: • Acute pericarditis due to connective tissue disease • Autoreactive (immune-mediated) pericarditis • Uremic pericarditis *NSAID of choice unless associated with acute MI, where all non-ASA NSAIDs should be avoided
Prognosis for acute idiopathic pericarditis • Good long-term prognosis • Cardiac tamponade is rare, but up to 70% in cases with specific etiologies (eg. Neoplastic, tuberculous, purulent) • Constrictive pericarditis occurs in about 1% of patients • 15-30% of patients not treated with colchicine develop either recurrent or incessant disease
Recurrent Pericarditis • Exact recurrence rate unknown • Most cases considered to be autoimmune • Risk Factors: • Lack of response to aspirin or other NSAID • Glucocorticoid therapy • Inappropriate pericardiotomy • Creation of a pericardial window • For some patients, symptoms can only be controlled with steroidal therapy
AutoreactivePericarditis: diagnostic criteria • Pericardial fluid revealing >5000/mm3 mononuclear cells or antisarcolemmal antibodies • Inflammation in epicardial/endomyocardial biopsies by >14 cells/mm2 • Exclusion of active viral infection both in pericardial effusion and endocardial/epicardial biopsies • Exclusion of tuberculosis, borreliaburgdorferi, chlamydiapneumoniae and other bacterial infection • Absence of neoplastic infiltration in effusion and biopsy samples • Exclusion of systemic, metabolic disorders and uremia
Treatment • Aspirin • NSAIDs • Colchicine: can reduce or eliminate need for glucocorticoids • Glucocorticoids: should be avoided unless required to treat patients who fail NSAID and colchicine therapy • Many believe that prednisone may perpetuate recurrences • Intrapericardialglucocorticoid therapy: sx improvement and prevention of recurrence in 90% of patients at 3 months and 84% at one year • Other immunosuppression • Azothoprine (75-100 mg/day) • Cyclophosphamide • Mycophenolate: anecdotal evidence only • Methotrexate: limited data • IVIG: limited data • Pericardiectomy: To avoid poor wound healing, recommended to be off prednisone for one year. Reserved for the following cases: • If >1 recurrence is accompanied by tamponade • If recurrence is principally manifested by persistent pain despite an intensive medical trial and evidence of serious glucocorticoid toxicity